Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Sembol: 002693.SZ
SHZ
6.14
CNYBugünkü piyasa fiyatı
-38.3977
F/K Oranı
-0.7680
PEG Oranı
2.55B
MRK Kapağı
- 0.00%
DIV Verimi
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Finansal Tablolar
Bilanço
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 291.41 | 31.9 | 146 | 77 | |||||||||||||||
balance-sheet.row.short-term-investments | 223.27 | 28.5 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.net-receivables | 97.01 | 16.4 | 41 | 33.1 | |||||||||||||||
balance-sheet.row.inventory | 306.61 | 74.3 | 65.4 | 55.2 | |||||||||||||||
balance-sheet.row.other-current-assets | 0.25 | 0.2 | 0 | 0.1 | |||||||||||||||
balance-sheet.row.total-current-assets | 721.6 | 135.2 | 252.4 | 165.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1823.92 | 457.6 | 471.8 | 504.7 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 688.05 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 688.05 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.long-term-investments | 44.81 | 10 | 8.8 | 17.3 | |||||||||||||||
balance-sheet.row.tax-assets | 4.76 | 1.5 | 1 | 1 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 83.17 | 27.1 | 12.2 | 9.1 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 2644.71 | 668 | 658.6 | 689.1 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 3366.32 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.account-payables | 61.58 | 17.1 | 15.5 | 17.2 | |||||||||||||||
balance-sheet.row.short-term-debt | 388.3 | 10.1 | 205.3 | 0.3 | |||||||||||||||
balance-sheet.row.tax-payables | 13.4 | 3.7 | 12.8 | 7.2 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 290.02 | 135 | 0 | 167 | |||||||||||||||
Deferred Revenue Non Current | 31.26 | 8 | 7.6 | 8.9 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 11.26 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 9.06 | 2 | 73.6 | 1.8 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 332.55 | 145.7 | 10.7 | 179.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-liab | 1177.06 | 285.6 | 330.1 | 287.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 68.85 | 34.4 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 1666.33 | 416.7 | 414.7 | 412 | |||||||||||||||
balance-sheet.row.retained-earnings | -1287.93 | -347 | -296.2 | -305.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 501.27 | -0.4 | 87.2 | 82.2 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1044.52 | 367.6 | 307.9 | 292.9 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 1993.04 | 471.5 | 513.5 | 481.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3366.32 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.minority-interest | 196.22 | 46.2 | 67.4 | 84.9 | |||||||||||||||
balance-sheet.row.total-equity | 2189.26 | 517.6 | 580.9 | 566.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3366.32 | - | - | - | |||||||||||||||
Total Investments | 206.63 | 10 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.total-debt | 678.32 | 145.1 | 205.3 | 167.3 | |||||||||||||||
balance-sheet.row.net-debt | 610.18 | 141.7 | 193.1 | 145.6 |
Nakit Akış Tablosu
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -63.99 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 40.38 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | -3.82 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 1.42 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | -10.62 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | 4.99 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | -12.45 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | -3.17 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | 45.94 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 7.88 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -50.56 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 14.27 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | -193.85 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 263.71 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 13.08 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 16.89 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | -92.11 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | -7.78 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 35.64 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -13.02 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.01 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 11.76 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 68.14 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 56.38 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | 7.88 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | -50.56 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | -42.68 | -7.8 | -8.1 | -62.1 |
Gelir Tablosu Satırı
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 197.21 | 235.9 | 274.8 | 320.3 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 68.14 | 74.9 | 88.3 | 81.4 | |||||||||||||||
income-statement-row.row.gross-profit | 129.06 | 161.1 | 186.5 | 238.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 8.41 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 20.73 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 80.37 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0.19 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.operating-expenses | 164.04 | 183.4 | 215.8 | 282.7 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 232.18 | 258.3 | 304.1 | 364.1 | |||||||||||||||
income-statement-row.row.interest-income | 0.04 | 0 | 0.1 | 0.1 | |||||||||||||||
income-statement-row.row.interest-expense | 9.04 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 80.37 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -58.06 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0.19 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -58.06 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.interest-expense | 9.04 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 32.98 | 52.7 | 57.5 | 54.3 | |||||||||||||||
income-statement-row.row.ebitda-caps | -31.85 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | -87.45 | -73.2 | -24.5 | -42.3 | |||||||||||||||
income-statement-row.row.income-before-tax | -87.26 | -73 | -8.9 | -40.4 | |||||||||||||||
income-statement-row.row.income-tax-expense | -12.63 | -1 | -0.4 | 0.4 | |||||||||||||||
income-statement-row.row.net-income | -63.99 | -50.7 | -8.5 | -40.8 |
Sıkça Sorulan Sorular
Nedir Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) toplam varlıklar?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) toplam varlıklar 803248121.000 şeklindedir.
İşletmenin yıllık geliri nedir?
Yıllık gelir 96442813.000'dur.
Firma kâr marjı nedir?
Firma kar marjı 0.654'dir.
Şirket serbest nakit akışı nedir?
Serbest nakit akışı -0.103'dur.
İşletme net kar marjı nedir?
Net kâr marjı -0.324'dir.
Firma toplam geliri nedir?
Toplam gelir -0.443'dur.
Nedir Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) net kar (net gelir)?
Net kar (net gelir) -50741578.370'dur.
Firmanın toplam borcu nedir?
Toplam borç 145050750.000'dir.
Faaliyet giderleri rakamı nedir?
İşletme giderleri 183423820.000'dır.
Şirket nakit rakamı nedir?
İşletme içi nakit 17684279.000'tir.